Gallein but not fluorescein enhances the PGD

G protein Gallein Gβɤ subunit Interleukin-6 Osteoblast Osteoprotegerin Prostaglandin D(2)

Journal

Prostaglandins, leukotrienes, and essential fatty acids
ISSN: 1532-2823
Titre abrégé: Prostaglandins Leukot Essent Fatty Acids
Pays: Scotland
ID NLM: 8802730

Informations de publication

Date de publication:
05 Sep 2024
Historique:
received: 04 07 2024
revised: 21 08 2024
accepted: 22 08 2024
medline: 14 9 2024
pubmed: 14 9 2024
entrez: 13 9 2024
Statut: aheadofprint

Résumé

Gallein, a small molecule related to fluorescein, is established as an inhibitor of Gβγ subunits to inhibit G protein (Gs) signaling. This agent is providing a potential therapeutic strategy to ameliorate organ dysfunctions especially involved in inflammation, however; the effects on bone metabolism have not yet been clarified. Prostaglandins (PGs) play important roles as autacoids including osteoblasts, and d-type prostanoid (DP) receptor, a member of G protein-coupled receptor specific to PGD

Identifiants

DOI: 10.1016/j.plefa.2024.102639 PMID: 39270488
pubmed: 39270488
pii: S0952-3278(24)00033-4
doi: 10.1016/j.plefa.2024.102639
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102639

Informations de copyright

Copyright © 2024 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have declared that there is no conflict of interest.

Auteurs

Tomoyuki Hioki (T)

Department of Pharmacology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan; Department of Dermatology, Central Japan International Medical Center, Minokamo 505-8510, Japan; Department of Metabolic Research, Research Institute, National Center for Geriatrics and Gerontology, Obu 474-8511, Japan.

Gen Kuroyanagi (G)

Department of Pharmacology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan; Department of Rehabilitation Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan.

Rie Matsushima-Nishiwaki (R)

Department of Pharmacology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan; Department of Metabolic Research, Research Institute, National Center for Geriatrics and Gerontology, Obu 474-8511, Japan.

Takuya Omura (T)

Department of Metabolic Research, Research Institute, National Center for Geriatrics and Gerontology, Obu 474-8511, Japan.

Osamu Kozawa (O)

Department of Pharmacology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan; Department of Metabolic Research, Research Institute, National Center for Geriatrics and Gerontology, Obu 474-8511, Japan.

Haruhiko Tokuda (H)

Department of Pharmacology, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan; Department of Metabolic Research, Research Institute, National Center for Geriatrics and Gerontology, Obu 474-8511, Japan; Department of Clinical Laboratory, Hospital, National Center for Geriatrics and Gerontology, Obu 474-8511, Japan. Electronic address: tokuda@ncgg.go.jp.

Classifications MeSH